The news: Novo Nordisk is terminating its short-lived partnership with Hims & Hers. The drugmaker is accusing Hims of illegally selling knockoff versions of Wegovy, while deceptively marketing its compounded GLP-1 products. Our take: Hims will likely regret its refusal to cooperate with Novo and Eli Lilly, who have taken control of the D2C weight loss drug market.
The news: Around 50 health plans— including large players UnitedHealthcare, CVS Health, Cigna, and Elevance Health—are pledging to simplify the prior authorization process. Our take: But their commitments don’t come with mandates or enforcement—meaning insurers can still get away with tactics that boost their profits over paying for expensive medical care.
The news: BetterHelp inked a deal with three WNBA teams to market and raise awareness of mental health services. Our take: Marketing healthcare products and services by making brand connections to aspirational healthiness via sports is a savvy strategic play for BetterHelp. The company’s lean into women’s sports, and especially tapping the surging popularity of the WNBA with relatable personal stories on Instagram, carves out a niche.
The news: The Trump administration is mulling new policies to make pharma advertising more difficult, per a Bloomberg report. Our take: RFK previously acknowledged the First Amendment hurdles in an outright pharma ad ban. But if he takes an alternate path with new D2C ad regulations, it’s a win for the industry. Pharma companies can budget for extra media costs of additional TV time and the loss of ad tax deductions, but they get to keep D2C advertising.
The news: Gilead’s long-lasting injection for HIV prevention received FDA approval, but the breakthrough drug comes with a high price tag ($28,218 annual list price). The takeaway: Another breakthrough drug with a high price tag adds fuel to the long-held idea that pharma puts profits over patients. Drugmakers need to offer and advertise practical solutions, such as direct financial help, and will need to fund more nonprofit programs to change perceptions.
The trend: Healthcare advertising motivates consumers to go online to do more research, or talk to a medical professional—but the majority of people have privacy concerns about personalized ads. Our take: Healthcare marketers are eager to use AI and targeting technology to make one-to-one connections with consumers. And it’s true that personalized ads can be more useful for people. However, marketers need to use transparent labeling, use conspicuous ad tags on social media, and preface targeted emails with explanations about why they’re being sent.
The trend: Younger generations continue to prioritize wellness more than older consumers and are purchasing products across a range of health and well-being categories. Our take: Sharing practical tips and advice is helpful, but brands and marketers can further stand out on social platforms by replying to users’ comments and questions within a post. Building partnerships with wellness influencers is essential, and it’s important to find creators who have real-life experiences that are relatable to the targeted audience.
The news: Oura is partnering with Maven Clinic to integrate smart ring data with providers’ care and treatment plans. Our take: We think it will take a while for providers to incorporate device data into the decisions they make for patients, which are typically based on clinical research studies and medical literature. Oura shouldn’t bet too heavily on securing doctors’ trust, and instead home in on the recent advancements it’s making on using AI to drive a better consumer experience.
The news: Prescription drug approval timelines will shrink under an FDA pilot program that will reduce the approval timelines from a typical 10 months to just 1 to 2 months. Our take: Speedier reviews and new AI programs for drug developers are good ideas, but pharma companies should remember the COVID-19 vaccines speed-to-market backlash and weigh the time benefit against whether their drugs will gain trust with physicians and patients.
The trend: Women see and hear more health-related information than men, especially when it comes to weight loss drugs and anti-aging treatments. Our take: Pharma and healthcare marketers need to more effectively reach women. Instead of marketing to all women, market to mindsets like self-care via social media influencers’ tips and advice, or motivations like caregiving and prevention by tapping into mammogram screening advocacy and resources that support overburdened women who care for loved ones.
The data: Around 2 in 5 employers and health plans will never consider covering GLP-1 drugs for obesity, according to a June 2025 report from Pharmaceutical Strategies Group. Our take: We don’t think a lack of insurance coverage for GLP-1s will lead to a market slowdown. Less generous insurance coverage of the drugs will force companies operating in the competitive cash-pay GLP-1 space to continue offering temporary discounts or lower their prices altogether.
The data: Nearly two-thirds of US adults (64%) have an unfavorable view of the House’s One Big Beautiful Bill Act, per KFF polling. Our take: If they aren’t already, healthcare marketers ought to be launching blitz campaigns about the bill’s potential ramifications. For instance, they could put pressure on lawmakers in the Senate by citing just-released study estimates that the proposed changes to Medicaid may result in ~25,000 preventable deaths annually due to how many patients will lose their physician, forgo needed medications, and put off screenings like mammograms.
The trend: Gen Z adults and boomers are more likely to strongly support vaccines for disease prevention than middle-aged generations. The takeaway: Gen Zers mirror older people’s pro-vaccine stance. This might be surprising, but it also presents an opportunity for brands and marketers who can no longer assume that young consumers are purely skeptical of the healthcare system. Marketers will want to tap influencers and edutainment to make sure accurate information on vaccines and other evidence-based treatments is readily available.
The news: Anne Wojcicki, the co-founder and CEO of 23andMe, is set to recoup control of the company after outbidding Regeneron Pharmaceuticals in a bankruptcy action. Our take: 23andMe will have a brand reputation problem assuming Wojcicki regains control. The company’s best path forward, considering past mistakes, is tapping into new consumer health and wellness categories rather than enterprise partnerships with pharma.
The news: Novo Nordisk missed an important patent filing deadline in Canada for its weight loss and diabetes drug semaglutide, opening the door to generics as soon as next year. Our take: If Sandoz and other generic makers start selling semaglutide GLP-1 drugs in Canada next year, FDA approval for states may not matter. If drugmakers do start selling generic GLP-1s in Canada, Novo will see Ozempic brand sales drop, but the GLP-1 market could see a generics’ explosion.
The news: Sens. Bernie Sanders (I-VT) and Angus King (I-ME) have introduced a bill, The End Prescription Drug Ads Now Act, that would prohibit D2C prescription drug advertising on television, radio, print, digital platforms, and social media. Our take: Despite disdain for drug commercials among consumers and lawmakers, pharma marketers shouldn’t sound the alarm just yet.
The data: Healthcare providers are struggling to get patients to use digital tools for scheduling appointments and paying for care, according to a recent Experian Health report. Our take: Clinic staff should gauge patients’ comfort level with using specific online tools at the first visit. These queries could give marketers the necessary information to remind people of the tech that’s available to them for accessing and managing their care. Further education around understanding medical bills and the importance of filling out pre-visit forms could drive patients to use a provider’s portal for these purposes.
The news: Novo Nordisk is partnering with AI drug discovery company Deep Apple Therapeutics to discover and develop new cardiometabolic drugs, including for obesity. The takeaway: Novo is not the biggest loser in the GLP-1 weight loss category, but it’s trailing Lilly in drug effectiveness, market value, and more importantly public perception. It’s critical for Novo to come up with new and better weight loss drugs—hence the deal with Deep Apple—but also polish its brand with consumers. A new CEO and new marketing direction could garner Novo some much-needed cachet.
The trend: Gen Z is turning to social media for job and career guidance in the UK, but typical pharma company content isn’t engaging them. The takeaway: Pharma and biotech companies need to embrace social media as serious recruiting channels to connect with Gen Z, and create unpolished, everyday snapshot-type videos with real employees. Social teams should track video trends on TikTok like “day in the life” or “put a finger down” and enlist employees to replicate them.
The news: Eli Lilly said it won’t partner with telehealth companies that sell compounded weight loss drugs. Our take: Lilly’s demand may signal that it’s in a better position in the weight loss drug market than Novo to play hardball with industry partners such as Hims & Hers.